Pathways creates personalized treatment plans for addiction, alcoholism, and depression using behavioral analytics and real-time progress tracking. The platform enhances patient engagement and improves recovery outcomes by delivering data-driven interventions tailored to individual needs.
Funding
Funding not disclosed
Founders
Product
Problem
Current treatments for neurological disorders, including alcohol use disorder, depression, and Juvenile Parkinson's Disease, often lack the specificity and long-term efficacy needed to significantly improve patient outcomes. Traditional pharmaceutical approaches may not address the underlying neurological mechanisms effectively, and can be limited by safety concerns.
Solution
Pathways Neuro Pharma develops gene therapy and pharmaceutical solutions focused on addressing the underlying neurological mechanisms of neurological disorders. Their platform utilizes an advanced expression plasmid to deliver therapeutic genes directly to the brain, offering a more efficient and safer method compared to traditional approaches. The plasmid is designed to sustain gene expression for an extended period, potentially leading to improved and more durable patient outcomes. Pathways is also developing combination therapies involving gene therapy to restore neuro-regulator levels and pharmaceutical activators to stimulate regulatory function.
Target Audience
The primary target audience includes individuals suffering from neurological disorders, particularly Juvenile Parkinson's Disease, and their families, as well as medical professionals specializing in neurology and gene therapy.
Features
- Advanced expression plasmid for targeted gene delivery to the brain.
- Sustained gene expression for up to 15 months.
- Combination therapy approach involving gene therapy and pharmaceutical activators.
- Focus on neurological disorders, including Juvenile Parkinson's Disease, alcohol use disorder, and depression.